Skip to main content
SpringerLink
Log in

Role of insulin-like growth factor-I in primary osteoporosis: A correlative study

  • Original Article
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Osteoporosis is characterized by impairment of bone mass and deterioration of bone microscopic structure, resulting in increased bone fragility and susceptibility to fracture. Recent reports have indicated that reduced plasma levels of IGF-I are associated with osteoporosis in both males and females. Moreover, there is accumulating clinical evidence that treatment with GH or IGF-I has beneficial effects on bone mass and bone remodeling in men with idiopathic osteoporosis, in the elderly and in hypopituitary patients. As correlative studies on IGF-I, IGF-BP3 and bone mass in the elderly are lacking, we studied the relationships between serum IGF-I, IGF-BP3, bone mineral density (BMD), body mass index (BMI), calciotropic hormones and age in 102 premenopausal and postmenopausal women. Our study indicates that the reduction of the anabolic processes mediated by IGF-I may account for the slow and progressive loss of bone mass that take place after the age of 40-50 years. In addition, nutritional caloric or proteic deficit may add to the effects of GH, age and other factors in decreasing IGF-I synthesis and therefore further contribute to the development of primary osteoporosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kanis J.A., Melton L.J. III, Christiansen C., Johnston C.C., Khaltaev N. The diagnosis of osteoporosis. J. Bone Min. Res. 1994, 9: 1137–1141.

    Article  CAS  Google Scholar 

  2. Rudman D. Growth hormone, body composition and aging. J. Am. Geriatr. Soc. 1985, 33: 800–807.

    CAS  PubMed  Google Scholar 

  3. Holly J.M.P., Wass J.A.H. Insulin-like growth factors: autocrine, paracrine or endocrine? New perspectives on the somatomedin hypothesis in the light of recent developments. J. Endocrinol. 1989, 122: 611–618.

    Article  CAS  PubMed  Google Scholar 

  4. Ljunghall S., Johansson A.G., Burman P., Kampe O., Lindh E., KarIsson F.A. Low plasma levels of insulin-like growth factor 1 (IGF-1) in male patients with idiopathic osteoporosis. J. Intern. Med. 1992, 232: 59–64.

    Article  CAS  PubMed  Google Scholar 

  5. Yamamoto H., Sohmiya M., Oka N., Kato Y. Effect of age and sex on plasma insulin-like growth factor 1 (IGF-1) levels in normal adults. Acta Endocrinol. 1991, 124: 497–500.

    CAS  PubMed  Google Scholar 

  6. Cuttler L., Van Vliet G., Conte F.A., Kaplan S.L., Grumbach M.M. Somatomedin-C levels in children and adolescence with gonadal dysgenesis. J. Clin. Endocrinol. Metab. 1985, 60: 1087–1092.

    Article  CAS  PubMed  Google Scholar 

  7. Jackson S., Undewood L.E., Clemmons D.R. Effect of calorie or protein restriction on insulin-like growth factor 1 (IGF-1) and IGF-binding proteins in children and adults. J. Clin. Endocrinol. Metab. 1995, 80: 443–449.

    Google Scholar 

  8. Moller S., Juul A., Becker U., Flyvbjerg A., Skakkebaek N.E., Henriksen J.H. Concentrations, release and disposal of insulin-like growth factor (IGF)-binding proteins (IGFBP), IGF-I and growth hormone in different vascular beds in patients with cirrhosis. J. Clin. Endocrinol. Metab. 1995, 80: 1148–1157.

    CAS  PubMed  Google Scholar 

  9. Froesch E.R., Hussain M.A., Schmid C., Zapf J. Insulin-like growth factor-I: physiology, metabolic effects and clinical uses. Diabetes Metab. Rev. 1996, 12: 195–215.

    Article  CAS  PubMed  Google Scholar 

  10. Blum W.F., Albertsson-WikIond K., Rosberg S., Forgensen L., Ranke M.B. Insulin-like growth factor binding protein (IGFBP-3) reflects spontaneous growth hormone (GH) secretion. Horm. Res. 1990, 33 (Suppl. 3): 3–9.

    Google Scholar 

  11. Kurland E.S., Rosen C.J., Cosman F., McMahon D., Chan F., Shane E., Lindsay R., Dempster D., Bilezikian J.P. Insulin-like growth factor-I in man with idiopathic osteoporosis. J. Clin. Endocrinol. Metab. 1997, 82: 2799–2805.

    CAS  PubMed  Google Scholar 

  12. Wuster C., Blum W.F., Schlemilch S., Ranke M.B., Ziegler R. Decreased serum levels of insulin-like growth factors and IGF binding protein 3 in osteoporosis. J. Intern. Med. 1993, 234: 249–255.

    Article  CAS  PubMed  Google Scholar 

  13. Sugimoto T., Nishiyama K., Kuribayashi F., Chihara K. Serum levels of insulin-like growth factor (IGF) 1, IGF-binding protein (IGFBP)-2, and IGFBP-3 in osteoporotic patients with and without spinal fractures. J. Bone Miner. Res. 1997, 12: 1272–1279.

    Article  CAS  PubMed  Google Scholar 

  14. Barret-Connor E., Goodman-Gruen D. Gender differences in insulin-like growth factor and bone mineral density association in old age: the Rancho Bernardo Study. J. Bone Miner. Res. 1998, 13: 1343–1349.

    Article  Google Scholar 

  15. Johansson A.G., Lindh E, Blum W.F. Effects of growth hormone and insulin-like growth factor 1 in men with idiopathic osteoporosis. J. Clin. Endocrinol. Metab. 1996, 81: 44–48.

    CAS  PubMed  Google Scholar 

  16. Marcus R., Butterfield G., Holloway L. Effects of short term administration of recombinant human growth hormone to elderly people. J. Clin. Endocrinol. Metab. 1990, 70: 519–527.

    Article  CAS  PubMed  Google Scholar 

  17. Johansson A.G., Rosen T., Bosaeus I. Two years of growth hormone (GH) treatment increases bone mineral content and density in hypopituitary patients with adult-onset GH deficiency. A double blind randomized placebo-controlled study. J. Clin. Endocrinol. Metab. 1996, 81: 3352–3359.

    Google Scholar 

  18. Calò L., Cantaro S., Marchini F., Giannini S., Castrignano R., Gambaro G., Antonello A., Baggio B., D’Angelo A., Williams H.E., Borsatti A. Is hydrochlorothiazide-induced hypocalciuria due to inhibition of prostaglandin E2 synthesis? Clin. Sci. 1990, 78: 321–325.

    PubMed  Google Scholar 

  19. Reid I.R., Plank L.D., Evans M.C. Fat mass is an important determinant of whole body bone density in premenopausal women but not in men. J. Clin. Endocrinol. Metab. 1992, 75: 779–782.

    CAS  PubMed  Google Scholar 

  20. Harris S., Dallal G.E., Dawson-Hughes B. Influence of body weight on rates of change in bone density of the spine, hip, and radius in postmenopausal women. Calcif. Tissue Inter. 1992, 50: 19–23.

    Article  CAS  Google Scholar 

  21. Harris S.T., Genant H.K., Baylink D.J., Gallagher J.C., Karp S.K., McConnell M.A., Green E.M., Stoll R.M. The effects of estrone (Ogen) on spinal bone density of postmenopausal women. Arch. Intern. Med. 1991, 151: 1980–1984.

    Article  CAS  PubMed  Google Scholar 

  22. Riggs B.L., Melton L.J. Involutional osteoporosis. N. Engl. J. Med. 1986, 314: 1676–1686.

    Article  CAS  PubMed  Google Scholar 

  23. Kurland E.S., Rosen C.J., Cosman F., McMahon D., Chan F., Shane E., Lindsay R., Dempster D., Bilezikian J.P. Insulin-like growth factor-I in man with idiopathic osteoporosis. J. Clin. Endocrinol. Metab. 1997, 82: 2799–2805.

    CAS  PubMed  Google Scholar 

  24. Wuster C., Blum W.F., Schlemilch S., Ranke M.B., Ziegler R. Decreased serum levels of insulin-like growth factors and IGF binding protein 3 in osteoporosis. J. Intern. Med. 1993, 234: 249–255.

    Article  CAS  PubMed  Google Scholar 

  25. Sugimoto T., Nishiyama K., Kuribayashi F., Chihara K. Serum levels of insulin-like growth factor (IGF) 1, IGF-binding protein (IGFBP)-2, and IGFBP-3 in osteoporotic patients with and without spinal fractures. J. Bone Miner. Res. 1997, 12: 1272–1279.

    Article  CAS  PubMed  Google Scholar 

  26. Barret-Connor E., Goodman-Gruen D. Gender differences in insulin-like growth factor and bone mineral density association in old age: the Rancho Bernardo Study. J. Bone Miner. Res. 1998, 13: 1343–1349.

    Article  Google Scholar 

  27. Johansson A.G., Lindh E, Blum W.F. Effects of growth hormone and insulin-like growth factor 1 in men with idiopathic osteoporosis. J. Clin. Endocrinol. Metab. 1996, 81: 44–48.

    CAS  PubMed  Google Scholar 

  28. Marcus R., Butterfield G., Holloway L. Effects of short term administration of recombinant human growth hormone to elderly people. J. Clin. Endocrinol. Metab. 1990, 70: 519–527.

    Article  CAS  PubMed  Google Scholar 

  29. Johansson A.G., Rosen T., Bosaeus I. Two years of growth hormone (GH) treatment increases bone mineral content and density in hypopituitary patients with adult-onset GH deficiency. A double blind randomized placebo-controlled study. J. Clin. Endocrinol. Metab. 1996, 81: 3352–3359.

    Google Scholar 

  30. Calò L., Cantaro S., Marchini F., Giannini S., Castrignano R., Gambaro G., Antonello A., Baggio B., D’Angelo A., Williams H.E., Borsatti A. Is hydrochlorothiazide-induced hypocalciuria due to inhibition of prostaglandin E2 synthesis? Clin. Sci. 1990, 78: 321–325.

    PubMed  Google Scholar 

  31. Reid I.R., Plank L.D., Evans M.C. Fat mass is an important determinant of whole body bone density in premenopausal women but not in men. J. Clin. Endocrinol. Metab. 1992, 75: 779–782.

    CAS  PubMed  Google Scholar 

  32. Harris S., Dallal G.E., Dawson-Hughes B. Influence of body weight on rates of change in bone density of the spine, hip, and radius in postmenopausal women. Calcif. Tissue Inter. 1992, 50: 19–23.

    Article  CAS  Google Scholar 

  33. Harris S.T., Genant H.K., Baylink D.J., Gallagher J.C., Karp S.K., McConnell M.A., Green E.M., Stoll R.M. The effects of estrone (Ogen) on spinal bone density of postmenopausal women. Arch. Intern. Med. 1991, 151: 1980–1984.

    Article  CAS  PubMed  Google Scholar 

  34. Riggs B.L., Melton L.J. Involutional osteoporosis. N. Engl. J. Med. 1986, 314: 1676–1686.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical and Experimental Medicine, Clinica Medica 4, University of Padova, Via Giustiniani 2, 35128, Padova, Italy

    L. Calò M.D., E. Pagnin & A. Semplicini

  2. Department of Medical and Surgical Sciences, Division of Nephrology, University of Padova, Italy

    R. Castrignano, G. Carraro & A. D’Angelo

  3. Clinica Medica 1, University of Padova, Italy

    R. Castrignano, G. Carraro & A. D’Angelo

  4. Department of Internal Medicine, Division of Clinical Nutrition, University of California, Davis, USA

    P. A. Davis & S. Giannini

Authors
  1. L. Calò M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Castrignano
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. A. Davis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. Carraro
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E. Pagnin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S. Giannini
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. Semplicini
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A. D’Angelo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L. Calò M.D..

Rights and permissions

Reprints and permissions

About this article

Cite this article

Calò, L., Castrignano, R., Davis, P.A. et al. Role of insulin-like growth factor-I in primary osteoporosis: A correlative study. J Endocrinol Invest 23, 223–227 (2000). https://doi.org/10.1007/BF03343711

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03343711

Key-words

Search

Navigation